They may cheer if Dr Reddy’s delivers on its promise of better growth in the second half of this fiscal year. In an interview published in the The Economic Times dated 13 June, Dr Reddy’s co-chairman and chief executive officer G.V. Dr Reddy’s acquisition of eight ANDAs, unlike an existing business, promises revenue only a few years down the lineThe sharp jump in Dr Reddy’s Laboratories Ltd free cash flows in FY16 hinted at the possibility of future acquisitions. Two, if Dr Reddy’s takes longer than expected to get its plants cleared by the US drug regulator, it becomes an insurance of sorts. One, this is a revenue stream that investors can look forward to, in 2018 and beyond.

Source: Mint June 13, 2016 20:30 UTC